Summary

The results of this large randomized controlled trial in patients with well-controlled lipid levels but who are at a high risk of cardiovascular events once again call into question the the clinical benefits of niacin despite an increase in high-density lipoprotein cholesterol (HDL-C), and reductions in triglyceride levels and low density lipoprotein cholesterol levels. This article presents the results of the Treatment of HDL to Reduce the Incidence of Vascular Events trial [HPS2-THRIVE Collaborative Group. Eur Heart J 2013].